

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Tree of Knowledge International Corp.** (the "Issuer").

Trading Symbol: **CSE: TOKI**

Number of Outstanding Listed Securities (March 31, 2019): **210,286,039 Common Shares**

Date: **April 5, 2019**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

***The Issuer has been pursuing its business plan. See Items 5 and 14.***

2. Provide a general overview and discussion of the activities of management.

***Management has spent the month actively pursuing its business plan and dealing with the combination of the business of Asterion Bio Med Inc. which it acquired in December 2018. See "Narrative Description of the Business" in the Listing Statement dated June 28, 2018.***

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and

acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

***On March 5, 2019, the Issuer announced that through its Toronto Poly Clinic (TPC) it entered into agreements with each of Pancare Consulting Inc.—owner of Pain Care Clinics (PCC) — and Onsite Medical Group for the operation of a multi-specialty pain management facility located within the new Jack Nathan Health® Medical Centre. The new facility will provide numerous services ranging from medical pain management, including medial cannabis treatment and using TPC's proven proprietary MCORP opioid reduction system, interventional pain management, psychological therapy, weight management, mindfulness meditation and physical therapy such as physiotherapy, chiropractic and massage. The facility is set to launch on March 7, 2019, at the Walmart store located at 8300 Hwy 27, Vaughan, ON. Pancare Consulting Inc. currently owns and operates 8 PCC clinics in various cities of Canada and services more than 100,000 patients. Onsite Medical Group provides physical rehabilitation and assessment services in 17 locations in Ontario.***

***On March 18, 2019, the Issuer announced that entered into a letter agreement (the "Letter Agreement") with Northern Green Canada Inc. ("NGC"), a licensed producer, to create a Strategic Alliance to serve the Medical Cannabis sector in Canada, with a longer term view to market expansion into the US and international markets through collaborating partnerships. Northern Green Canada is a private, federally licensed cannabis producer based in Ontario, focused on providing high quality, pharmaceutical grade products for enhanced quality of life. NGC was founded by a drive to create a company dedicated to helping others through the responsible use and innovation of medical cannabis. They operate out of their 90,000 square foot location in Brampton, Ontario, equipped with state-of-the-art cultivation facilities. NGC is currently selling flower and is in the process of having its license amended to include oils. In addition to an expert grow team, NGC management includes medical doctors and pharmaceutical personnel. NGC is aligned with respected partners to develop cannabis-infused edibles and drinks to broaden its product portfolio as legislation permits.***

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a

schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None.**

8. Describe the acquisition of new customers or loss of customers.

**None.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

***The Issuer terminated Cliff Henley, Vice President Operations of the Issuer, responsible for the Company's US and South American operations.***

11. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Common Shares	1,363,635	Issued in connection with a private placement	\$300,000.00 working capital
Common Shares	205,523	Issue upon the exercise of warrants	\$30,828.45 working capital
Common Shares	944,055	Issued in connection with consulting agreements	n/a issued for Services rendered

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

***The Issuer owes one of its principals – Brian Main an aggregate sum of US\$197,726.50. The Issuer entered into a promissory note with Mr. Main dated effective September 1, 2018, to evidence this historical debt. The amount is due December 31, 2019 and bears no interest (see also Item 13 above). In addition, the Issuer entered into a grid promissory note dated effective October 1, 2018, with each of the principals as to US\$145,839.60 for Brian Main and US\$285,305.52 for Michael Caridi. The amounts are due December 31, 2020, and bear no interest. The notes are repayable as to \$20,000 per month per note starting January 1, 2019. The repayments have not yet commenced.***

16. Provide details of any changes in directors, officers or committee members.

***None.***

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

***The use of cannabis and its general acceptance, particularly for medical uses, continues to grow in the United States, Canada and internationally, as evidenced by the increasing number of jurisdictions adopting regulations to govern its use. However, it is not legal at the federal level in the United States and Canada has yet to implement its legalization process. CBD, in particular has garnered recent attention for efficacy in a variety of products, most notably, for the treatment of rare epileptic related disorders in children, however, until recently the legal status of CBD in the United States at a federal level was also tied to cannabis generally.***

***On December 20, 2018, the Agriculture Improvement Act of 2018 (the "2018 Farm Bill") was passed into law. Marked as genuinely historic for the cannabis industry, the passing of the 2018 Farm Bill has removed all confusion associated with "industrial hemp". While the Issuer has always utilized organically sourced US Dept. of Agriculture approved industrial hemp in its products, "hemp", defined as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis," has now been officially removed from the Controlled Substances Act in the United States. While the Issuer is still assessing the various implications of the new law, the development is extremely positive for the Issuer and its future development plans in the U.S. and elsewhere. See "Narrative Description of the Business – Regulatory Considerations" in the Listing Statement.***

***CBD has also been cited for benefits in the treatment of schizophrenia, some forms of cancer, type 1 diabetes, Alzheimer's, post-traumatic stress disorder, pain and inflammation, anxiety, addictions, mood symptoms, insomnia and acne. See "Narrative Description of the Business – Principal Products or Services" in the Listing Statement. A recent trend includes use of CBD in the beauty products industry. Evidence of the benefits appears to be primarily anecdotal, however, an increasing number of studies and trials are being conducted to test the efficacy of CBD, particularly internationally. There are also an increasing number of delivery methods including vaporizers, oils, sprays, creams, capsules and microencapsulation (a process for putting CBD into tiny capsules to make it more***

*readily absorbed by the body). As demand increases we can expect to see a number of technological advances.*

*The safety of CBD and cannabis related products will remain of paramount importance for the Issuer and will continue to be a focus for consumers and regulators alike. Regulation of the industry is expected to increase, including new regulations anticipated from the US Food and Drug Administration (FDA). Despite these challenges and a general lack of access to banking, the cannabis industry has so far enjoyed access to capital markets. The situation is constantly evolving and there is a great degree of uncertainty over how matters will be settled, however, it is likely that these US states that have legalized cannabis will fight any prohibition on its use as they are receiving significant amounts of tax revenue from the sale of cannabis. See “Narrative Description of the Business – Regulatory Considerations” and “Risk Factors” in the Listing Statement.*

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 5, 2019.

Scott Reeves

Name of Director or Senior Officer



Signature

Director and Secretary

Official Capacity

<b>Issuer Details</b> Name of Issuer <b>TREE OF KNOWLEDGE INTERNATIONAL CORP.</b>	For Month End <b>March</b>	Date of Report YY/MM/D <b>19/04/05</b>
Issuer Address <b>633 Coronation Drive, Unit 645</b>		
City/Province/Postal Code <b>Scarborough, ON M1E 2K4</b>	Issuer Fax No. (   )	Issuer Telephone No. <b>1-877-283-1569</b>
Contact Name <b>Michael Caridi</b>	Contact Position <b>Interim CFO</b>	Contact Telephone No. <b>(917)295-1374</b>
Contact Email Address <b>michael@evrcbd.com</b>	Web Site Address <a href="http://www.tokicorp.ca">www.tokicorp.ca</a>	